Van Maele P, Willocx R
Ann Gastroenterol Hepatol (Paris). 1985 Jul-Sep;21(4):221-6.
From controlled studies only, the authors state the true position of medical therapeutics for the Crohn's disease when it attacks the small intestine and the colon. Sulfasalazine remains the first rate medicine, essentially when the ileum and colon, or colon alone, becomes affected. Metronidazole seems as effective, indeed slightly more so. Corticotherapy should be kept for patients who do not react to sulfasalazine or whose disease is, at the onset, particularly active. The duration of the corticotherapy should be the shortest possible. Immunosuppressors do not seem to be of any help in acute phase and their effect shows only after several months. Their main interest resides in the possibility of reducing or stopping the corticosteroids treatment. There is not enough information about the other medications that have been the tried to draw any conclusions. The use of pure 5-aminosalicylic acid or associated to another vector such as sulfapyridine, will probably be an important therapeutical progress.
仅从对照研究来看,作者阐述了医学治疗方法在克罗恩病侵袭小肠和结肠时的真实地位。柳氮磺胺吡啶仍是首选药物,尤其是在回肠和结肠或仅结肠受累时。甲硝唑似乎同样有效,实际上效果稍好一些。对于对柳氮磺胺吡啶无反应或疾病在发病时特别活跃的患者,应采用皮质激素疗法。皮质激素疗法的持续时间应尽可能短。免疫抑制剂在急性期似乎并无帮助,其效果仅在数月后才显现。它们的主要优势在于有可能减少或停止皮质类固醇治疗。关于其他已尝试的药物,尚无足够信息得出任何结论。使用纯5-氨基水杨酸或与另一种载体如磺胺吡啶联合使用,可能将是一项重要的治疗进展。